Anti-Human VEGF (Bevacizumab) – Fc Muted™ Biotin
Pricing & Details
Antibody DetailsProduct DetailsReactivity Species Human Host Species Human Expression Host HEK-293 FC Effector Activity Muted Immunogen Recombinant human VEGF. Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Reported Applications For Relevant Conjugates ? B N IP WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only. Antigen Distribution VEGF is widely expressed in the thyroid, prostate, and various other tissues. Background Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects. Antigen DetailsProtein PubMed NCBI Gene Bank ID UniProt.org References & Citations1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70. Technical Protocols  |
Formats Available
Prod No. | Description |
|---|---|
LT400 |
|
LT405 |
|
LT401 |
|
LT402 |
|
LT406 |
|
LT407 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.